Choline for Health & Longevity - Quick Reference Sheet

Choline for Health & Longevity

Created on 10/17/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Choline, an essential nutrient found mainly in eggs, liver, meat, fish and soy and sold as a dietary supplement, helps build cell membranes, export fat from the liver and support memory. Most adults eat below the official target. Too little causes liver fat build-up, reversed by restoring it. Adequate intake tracks with better memory and lower dementia risk; heart concerns remain unresolved. Evidence supports adequacy far more than high-dose supplementation. (Full Review)

Protocol

Adequacy target (food-first approach)
550 mg/day men · 425 mg/day women
One large egg supplies about 147 mg; total intake kept below the 3.5 g/day upper limit
Gap-filling supplement
Phosphatidylcholine, bitartrate or citrate
Supplies only the shortfall below the Adequate Intake; phosphatidylcholine avoids the surge in TMAO, a heart-risk-linked compound gut microbes make from choline
Targeted cognitive approach
Citicoline 500 mg/day
One daily dose with breakfast; 12-week memory trial in adults aged 50–85
Time to effect
Liver recovery on restored intake
Within 4 weeks
Deficiency-related liver changes improved within 4 weeks of restoring choline in intravenous feeding
Liver changes on low intake
Within 3 weeks
Deficiency-related liver changes appear within 3 weeks of low intake
Memory (citicoline)
12 weeks
Memory effects of citicoline were measured at 12 weeks

Benefits

Contraindications
  • Trimethylaminuria (inherited inability to clear fishy-smelling trimethylamine; FMO3 deficiency)
  • Total intake above the 3.5 g/day upper limit
  • Chronic kidney disease (eGFR below 60), for choline salts beyond food intake
  • Adults aged 50 and older, for long-term alpha-GPC (caution; observational)
  • Men, for intake well above the Adequate Intake (caution; observational; lethal prostate-cancer incidence, not survival)
Key Interactions
  • Cholinesterase inhibitors (dementia drugs that slow acetylcholine breakdown; donepezil, rivastigmine, galantamine): Monitor
  • Anticholinergic drugs (drugs that block acetylcholine; oxybutynin, tolterodine, amitriptyline): Monitor (theoretical)
  • Levodopa (carbidopa-levodopa): Monitor
  • Low-dose aspirin (over-the-counter): Monitor
  • First-generation antihistamines (diphenhydramine, doxylamine; over-the-counter): Monitor (theoretical)
  • Broad-spectrum antibiotics (ciprofloxacin, metronidazole): Minor
  • Methotrexate: Caution (theoretical)
  • Other cholinergic supplements (huperzine A, galantamine-containing memory-support blends): Caution (theoretical)
  • Other TMAO precursors (L-Carnitine supplements): Caution (theoretical)

Risk & Side Effects

  • Medium: Colorectal adenoma in women
  • Low: Cardiovascular disease, stroke and mortality (conflicted); lethal prostate cancer (conflicted); type 2 diabetes (conflicted); fishy body odor, sweating, digestive upset and low blood pressure at multi-gram doses

Monitoring

Marker Target Why
ALT (alanine aminotransferase) 29–33 IU/L or lower (men); 19–25 IU/L or lower (women) Rises with choline deficiency, falls when intake is restored
Liver fat (FibroScan CAP) No established target; track change from own baseline Deficiency adds liver fat
Homocysteine 5–15 µmol/L Phosphatidylcholine lowers it
TMAO (fasting plasma) No established target; track change from own baseline Safety check: a marked rise prompts switching form or reducing dose
eGFR (kidney function) 60 mL/min/1.73 m² or higher Safety check: reduced kidney function changes form and dose choice

Cadence: Baseline before starting; repeat at 3 months, then every 6–12 months while supplementing

Qualitative Assessment

  • Memory, focus and mental clarity during demanding work
  • Energy levels and exercise performance
  • Digestive comfort (absence of nausea or diarrhea)
  • Body odor (absence of a fishy smell)
  • Sleep quality when taking citicoline or alpha-GPC